A number of related drugs for type 2 diabetics may boost their risk of heart failure, a Wake Forest University School of Medicine study finds.
Thiazolidinediones, which regulate users' blood sugar, appear to double the risk of congestive heart failure among people with type 2 diabetes, study authors Dr. Sonal Singh and Dr. Curt Furberg said in editorial published in the journal Heart.
Drugs in this class include rosiglitazone (Avandia) and pioglitazone (Actos), reports United Press International.
Almost one-quarter of diabetics also have some form of heart disease, the wire service said. More than half of elderly diabetics will develop congestive heart failure, the study authors wrote.